Risk factors associated with anaphylaxis and other allergic-like events following receipt of 2009 monovalent AS03-adjuvanted pandemic influenza vaccine in Quebec, Canada
Identifieur interne : 001D22 ( PascalFrancis/Curation ); précédent : 001D21; suivant : 001D23Risk factors associated with anaphylaxis and other allergic-like events following receipt of 2009 monovalent AS03-adjuvanted pandemic influenza vaccine in Quebec, Canada
Auteurs : Isabelle Rouleau [Canada] ; Gaston De Serres [Canada] ; Danuta M. Skowronski [Canada] ; Jean Philippe Drolet [Canada] ; Chantal Lemired [Canada] ; Eveline Toth [Canada] ; Monique Landry [Canada]Source :
- Vaccine [ 0264-410X ] ; 2014.
Descripteurs français
- Pascal (Inist)
- Wicri :
English descriptors
- KwdEn :
Abstract
Introduction: In Quebec, Canada, receipt of the 2009 AS03-adjuvanted pandemic H1N1 vaccine was associated with increased risk of anaphylaxis and other allergic-like events (ALE), especially among women of childbearing age. In response to this safety signal, a case-control study was conducted to identify potential risk factors. Methods: A total of 435 ALE (50 anaphylaxis) occurring <24 h following pandemic vaccination were compared to 849 age-gender matched controls randomly selected from the provincial Pandemic Influenza Vaccination Registry. More than 60 potential risk factors were evaluated through phone interviews and included demographic information, medical history, medication use or acute respiratory illnesses (ARI) concurrent with vaccination and other risk factors associated with general allergy. Odds ratios (ORs) with 95% confidence intervals were estimated with unconditional logistic regression. Results: Factors associated with increased risk of anaphylaxis included concurrent ARI (18% cases vs. 4% controls, ORadj 7.67, 95%CI: 3.04-13.37), food allergy (26% cases vs. 4% controls, ORadj 3.84, 95%CI: 1.51-9.74) and vaccination during the first four weeks of the campaign (66% cases vs. 50% controls, ORadj 2.16,95%CI: 1.10-4.25) whereas alcohol exposure (≥1 drink/week) was associated with reduced risk (29% cases vs. 42% controls, ORadj 0.26,95%CI: 0.13-0.57). These factors were also significantly associated with any ALE but the strength of association was weaker. Allergy to components found in the vaccine (e.g., egg, thimerosal) was infrequent and did not significantly differ between cases and controls. Conclusion: Increased anaphylaxis and other allergic-like events observed in association with AS03-adjuvanted pandemic H1N1 vaccine remain mostly unexplained despite extensive risk factor review. However, prior to mass vaccination with similar formulations this safety signal warrants further consideration and better understanding. In particular, the predominance among women of childbearing age may be a clue to underlying biological or hormonal influences on adverse immunological responses to vaccine.
| pA |
|
|---|
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000097
Links to Exploration step
Pascal:14-0143864Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Risk factors associated with anaphylaxis and other allergic-like events following receipt of 2009 monovalent AS03-adjuvanted pandemic influenza vaccine in Quebec, Canada</title><author><name sortKey="Rouleau, Isabelle" sort="Rouleau, Isabelle" uniqKey="Rouleau I" first="Isabelle" last="Rouleau">Isabelle Rouleau</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Centre hospitalier universitaire de Quebec</s1><s2>Quebec City, Quebec</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>Canada</country></affiliation></author><author><name sortKey="De Serres, Gaston" sort="De Serres, Gaston" uniqKey="De Serres G" first="Gaston" last="De Serres">Gaston De Serres</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Centre hospitalier universitaire de Quebec</s1><s2>Quebec City, Quebec</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>Canada</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Institut national de santé publique du Québec</s1><s2>Quebec</s2><s3>CAN</s3><sZ>2 aut.</sZ></inist:fA14><country>Canada</country></affiliation></author><author><name sortKey="Skowronski, Danuta M" sort="Skowronski, Danuta M" uniqKey="Skowronski D" first="Danuta M." last="Skowronski">Danuta M. Skowronski</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>British Columbia Centre for Disease Control</s1><s2>Vancouver</s2><s3>CAN</s3><sZ>3 aut.</sZ></inist:fA14><country>Canada</country></affiliation></author><author><name sortKey="Drolet, Jean Philippe" sort="Drolet, Jean Philippe" uniqKey="Drolet J" first="Jean Philippe" last="Drolet">Jean Philippe Drolet</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Centre hospitalier universitaire de Quebec</s1><s2>Quebec City, Quebec</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>Canada</country></affiliation></author><author><name sortKey="Lemired, Chantal" sort="Lemired, Chantal" uniqKey="Lemired C" first="Chantal" last="Lemired">Chantal Lemired</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Centre hospitalier universitaire de Sherbrooke, Faculté de médecine et des sciences de la santé, Université de Sherbrooke</s1><s2>Sherbrooke, Québec</s2><s3>CAN</s3><sZ>5 aut.</sZ></inist:fA14><country>Canada</country></affiliation></author><author><name sortKey="Toth, Eveline" sort="Toth, Eveline" uniqKey="Toth E" first="Eveline" last="Toth">Eveline Toth</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Ministère de la santé et des services sociaux du Québec</s1><s2>Montréal, Québec</s2><s3>CAN</s3><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>Canada</country></affiliation></author><author><name sortKey="Landry, Monique" sort="Landry, Monique" uniqKey="Landry M" first="Monique" last="Landry">Monique Landry</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Ministère de la santé et des services sociaux du Québec</s1><s2>Montréal, Québec</s2><s3>CAN</s3><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>Canada</country></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">14-0143864</idno><date when="2014">2014</date><idno type="stanalyst">PASCAL 14-0143864 INIST</idno><idno type="RBID">Pascal:14-0143864</idno><idno type="wicri:Area/PascalFrancis/Corpus">000097</idno><idno type="wicri:Area/PascalFrancis/Curation">001D22</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Risk factors associated with anaphylaxis and other allergic-like events following receipt of 2009 monovalent AS03-adjuvanted pandemic influenza vaccine in Quebec, Canada</title><author><name sortKey="Rouleau, Isabelle" sort="Rouleau, Isabelle" uniqKey="Rouleau I" first="Isabelle" last="Rouleau">Isabelle Rouleau</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Centre hospitalier universitaire de Quebec</s1><s2>Quebec City, Quebec</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>Canada</country></affiliation></author><author><name sortKey="De Serres, Gaston" sort="De Serres, Gaston" uniqKey="De Serres G" first="Gaston" last="De Serres">Gaston De Serres</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Centre hospitalier universitaire de Quebec</s1><s2>Quebec City, Quebec</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>Canada</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Institut national de santé publique du Québec</s1><s2>Quebec</s2><s3>CAN</s3><sZ>2 aut.</sZ></inist:fA14><country>Canada</country></affiliation></author><author><name sortKey="Skowronski, Danuta M" sort="Skowronski, Danuta M" uniqKey="Skowronski D" first="Danuta M." last="Skowronski">Danuta M. Skowronski</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>British Columbia Centre for Disease Control</s1><s2>Vancouver</s2><s3>CAN</s3><sZ>3 aut.</sZ></inist:fA14><country>Canada</country></affiliation></author><author><name sortKey="Drolet, Jean Philippe" sort="Drolet, Jean Philippe" uniqKey="Drolet J" first="Jean Philippe" last="Drolet">Jean Philippe Drolet</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Centre hospitalier universitaire de Quebec</s1><s2>Quebec City, Quebec</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>Canada</country></affiliation></author><author><name sortKey="Lemired, Chantal" sort="Lemired, Chantal" uniqKey="Lemired C" first="Chantal" last="Lemired">Chantal Lemired</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Centre hospitalier universitaire de Sherbrooke, Faculté de médecine et des sciences de la santé, Université de Sherbrooke</s1><s2>Sherbrooke, Québec</s2><s3>CAN</s3><sZ>5 aut.</sZ></inist:fA14><country>Canada</country></affiliation></author><author><name sortKey="Toth, Eveline" sort="Toth, Eveline" uniqKey="Toth E" first="Eveline" last="Toth">Eveline Toth</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Ministère de la santé et des services sociaux du Québec</s1><s2>Montréal, Québec</s2><s3>CAN</s3><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>Canada</country></affiliation></author><author><name sortKey="Landry, Monique" sort="Landry, Monique" uniqKey="Landry M" first="Monique" last="Landry">Monique Landry</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Ministère de la santé et des services sociaux du Québec</s1><s2>Montréal, Québec</s2><s3>CAN</s3><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>Canada</country></affiliation></author></analytic><series><title level="j" type="main">Vaccine</title><title level="j" type="abbreviated">Vaccine</title><idno type="ISSN">0264-410X</idno><imprint><date when="2014">2014</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Vaccine</title><title level="j" type="abbreviated">Vaccine</title><idno type="ISSN">0264-410X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Allergy</term><term>Anaphylaxis</term><term>Hypersensitivity</term><term>Immunological adjuvant</term><term>Influenza</term><term>Quebec</term><term>Risk factor</term><term>Toxicity</term><term>Vaccine</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Facteur risque</term><term>Anaphylaxie</term><term>Adjuvant immunologique</term><term>Vaccin</term><term>Québec</term><term>Toxicité</term><term>Hypersensibilité</term><term>Allergie</term><term>Grippe</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Vaccin</term><term>Allergie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Introduction: In Quebec, Canada, receipt of the 2009 AS03-adjuvanted pandemic H1N1 vaccine was associated with increased risk of anaphylaxis and other allergic-like events (ALE), especially among women of childbearing age. In response to this safety signal, a case-control study was conducted to identify potential risk factors. Methods: A total of 435 ALE (50 anaphylaxis) occurring <24 h following pandemic vaccination were compared to 849 age-gender matched controls randomly selected from the provincial Pandemic Influenza Vaccination Registry. More than 60 potential risk factors were evaluated through phone interviews and included demographic information, medical history, medication use or acute respiratory illnesses (ARI) concurrent with vaccination and other risk factors associated with general allergy. Odds ratios (ORs) with 95% confidence intervals were estimated with unconditional logistic regression. Results: Factors associated with increased risk of anaphylaxis included concurrent ARI (18% cases vs. 4% controls, ORadj 7.67, 95%CI: 3.04-13.37), food allergy (26% cases vs. 4% controls, ORadj 3.84, 95%CI: 1.51-9.74) and vaccination during the first four weeks of the campaign (66% cases vs. 50% controls, ORadj 2.16,95%CI: 1.10-4.25) whereas alcohol exposure (≥1 drink/week) was associated with reduced risk (29% cases vs. 42% controls, ORadj 0.26,95%CI: 0.13-0.57). These factors were also significantly associated with any ALE but the strength of association was weaker. Allergy to components found in the vaccine (e.g., egg, thimerosal) was infrequent and did not significantly differ between cases and controls. Conclusion: Increased anaphylaxis and other allergic-like events observed in association with AS03-adjuvanted pandemic H1N1 vaccine remain mostly unexplained despite extensive risk factor review. However, prior to mass vaccination with similar formulations this safety signal warrants further consideration and better understanding. In particular, the predominance among women of childbearing age may be a clue to underlying biological or hormonal influences on adverse immunological responses to vaccine.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0264-410X</s0></fA01><fA02 i1="01"><s0>VACCDE</s0></fA02><fA03 i2="1"><s0>Vaccine</s0></fA03><fA05><s2>32</s2></fA05><fA06><s2>28</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Risk factors associated with anaphylaxis and other allergic-like events following receipt of 2009 monovalent AS03-adjuvanted pandemic influenza vaccine in Quebec, Canada</s1></fA08><fA11 i1="01" i2="1"><s1>ROULEAU (Isabelle)</s1></fA11><fA11 i1="02" i2="1"><s1>DE SERRES (Gaston)</s1></fA11><fA11 i1="03" i2="1"><s1>SKOWRONSKI (Danuta M.)</s1></fA11><fA11 i1="04" i2="1"><s1>DROLET (Jean Philippe)</s1></fA11><fA11 i1="05" i2="1"><s1>LEMIRED (Chantal)</s1></fA11><fA11 i1="06" i2="1"><s1>TOTH (Eveline)</s1></fA11><fA11 i1="07" i2="1"><s1>LANDRY (Monique)</s1></fA11><fA14 i1="01"><s1>Centre hospitalier universitaire de Quebec</s1><s2>Quebec City, Quebec</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ></fA14><fA14 i1="02"><s1>Institut national de santé publique du Québec</s1><s2>Quebec</s2><s3>CAN</s3><sZ>2 aut.</sZ></fA14><fA14 i1="03"><s1>British Columbia Centre for Disease Control</s1><s2>Vancouver</s2><s3>CAN</s3><sZ>3 aut.</sZ></fA14><fA14 i1="04"><s1>Centre hospitalier universitaire de Sherbrooke, Faculté de médecine et des sciences de la santé, Université de Sherbrooke</s1><s2>Sherbrooke, Québec</s2><s3>CAN</s3><sZ>5 aut.</sZ></fA14><fA14 i1="05"><s1>Ministère de la santé et des services sociaux du Québec</s1><s2>Montréal, Québec</s2><s3>CAN</s3><sZ>6 aut.</sZ><sZ>7 aut.</sZ></fA14><fA20><s1>3480-3487</s1></fA20><fA21><s1>2014</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>20289</s2><s5>354000507544400030</s5></fA43><fA44><s0>0000</s0><s1>© 2014 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>34 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>14-0143864</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Vaccine</s0></fA64><fA66 i1="01"><s0>GBR</s0></fA66><fC01 i1="01" l="ENG"><s0>Introduction: In Quebec, Canada, receipt of the 2009 AS03-adjuvanted pandemic H1N1 vaccine was associated with increased risk of anaphylaxis and other allergic-like events (ALE), especially among women of childbearing age. In response to this safety signal, a case-control study was conducted to identify potential risk factors. Methods: A total of 435 ALE (50 anaphylaxis) occurring <24 h following pandemic vaccination were compared to 849 age-gender matched controls randomly selected from the provincial Pandemic Influenza Vaccination Registry. More than 60 potential risk factors were evaluated through phone interviews and included demographic information, medical history, medication use or acute respiratory illnesses (ARI) concurrent with vaccination and other risk factors associated with general allergy. Odds ratios (ORs) with 95% confidence intervals were estimated with unconditional logistic regression. Results: Factors associated with increased risk of anaphylaxis included concurrent ARI (18% cases vs. 4% controls, ORadj 7.67, 95%CI: 3.04-13.37), food allergy (26% cases vs. 4% controls, ORadj 3.84, 95%CI: 1.51-9.74) and vaccination during the first four weeks of the campaign (66% cases vs. 50% controls, ORadj 2.16,95%CI: 1.10-4.25) whereas alcohol exposure (≥1 drink/week) was associated with reduced risk (29% cases vs. 42% controls, ORadj 0.26,95%CI: 0.13-0.57). These factors were also significantly associated with any ALE but the strength of association was weaker. Allergy to components found in the vaccine (e.g., egg, thimerosal) was infrequent and did not significantly differ between cases and controls. Conclusion: Increased anaphylaxis and other allergic-like events observed in association with AS03-adjuvanted pandemic H1N1 vaccine remain mostly unexplained despite extensive risk factor review. However, prior to mass vaccination with similar formulations this safety signal warrants further consideration and better understanding. In particular, the predominance among women of childbearing age may be a clue to underlying biological or hormonal influences on adverse immunological responses to vaccine.</s0></fC01><fC02 i1="01" i2="X"><s0>002A05F04</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Facteur risque</s0><s5>05</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Risk factor</s0><s5>05</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Factor riesgo</s0><s5>05</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Anaphylaxie</s0><s5>06</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Anaphylaxis</s0><s5>06</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Anafilaxia</s0><s5>06</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Adjuvant immunologique</s0><s5>07</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Immunological adjuvant</s0><s5>07</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Coadyuvante inmunológico</s0><s5>07</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Vaccin</s0><s5>08</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Vaccine</s0><s5>08</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Vacuna</s0><s5>08</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Québec</s0><s2>NG</s2><s5>09</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Quebec</s0><s2>NG</s2><s5>09</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Quebec</s0><s2>NG</s2><s5>09</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Toxicité</s0><s5>11</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Toxicity</s0><s5>11</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Toxicidad</s0><s5>11</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Hypersensibilité</s0><s5>12</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Hypersensitivity</s0><s5>12</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Hipersensibilidad</s0><s5>12</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Allergie</s0><s5>14</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Allergy</s0><s5>14</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Alergia</s0><s5>14</s5></fC03><fC03 i1="09" i2="X" l="FRE"><s0>Grippe</s0><s5>15</s5></fC03><fC03 i1="09" i2="X" l="ENG"><s0>Influenza</s0><s5>15</s5></fC03><fC03 i1="09" i2="X" l="SPA"><s0>Gripe</s0><s5>15</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Canada</s0><s2>NG</s2></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Canada</s0><s2>NG</s2></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Canadá</s0><s2>NG</s2></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Amérique du Nord</s0><s2>NG</s2></fC07><fC07 i1="02" i2="X" l="ENG"><s0>North America</s0><s2>NG</s2></fC07><fC07 i1="02" i2="X" l="SPA"><s0>America del norte</s0><s2>NG</s2></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Amérique</s0><s2>NG</s2></fC07><fC07 i1="03" i2="X" l="ENG"><s0>America</s0><s2>NG</s2></fC07><fC07 i1="03" i2="X" l="SPA"><s0>America</s0><s2>NG</s2></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Immunopathologie</s0><s5>13</s5></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Immunopathology</s0><s5>13</s5></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Inmunopatología</s0><s5>13</s5></fC07><fC07 i1="05" i2="X" l="FRE"><s0>Virose</s0></fC07><fC07 i1="05" i2="X" l="ENG"><s0>Viral disease</s0></fC07><fC07 i1="05" i2="X" l="SPA"><s0>Virosis</s0></fC07><fC07 i1="06" i2="X" l="FRE"><s0>Infection</s0></fC07><fC07 i1="06" i2="X" l="ENG"><s0>Infection</s0></fC07><fC07 i1="06" i2="X" l="SPA"><s0>Infección</s0></fC07><fN21><s1>181</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard></inist></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PascalFrancis/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001D22 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 001D22 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= PascalFrancis
|étape= Curation
|type= RBID
|clé= Pascal:14-0143864
|texte= Risk factors associated with anaphylaxis and other allergic-like events following receipt of 2009 monovalent AS03-adjuvanted pandemic influenza vaccine in Quebec, Canada
}}
| This area was generated with Dilib version V0.6.34. |  |